TABLE 1.

Characteristics at baseline among resiquimod and vehicle patients

ParameterPatient groupPa
Vehicle (n = 39)Resiquimod (n = 43)
Mean age in yr (SD)39.8 (9.6)38.3 (11.3)0.536*
Sex
    No. of females (%)23 (59)29 (67)0.495†
    No. of males (%)16 (41)14 (33)
Race: no. of subjects (%)
    White32 (82)24 (79)0.786†
    Black6 (15)8 (19)
    Other1 (3)1 (2)
Median time in mo since diagnosis (range)130 (9-393)102 (7-390)0.500*
Median time in days since last recurrence (range)27 (1-263)32 (2-343)0.455*
Median no. of recurrences per year (range) in past 12 mo7 (4-52)6 (4-15)0.215*
Median duration in days (range) of last recurrence7 (2-14)5 (2-18)0.231*
No. of subjects (%) with the indicated serostatus
    HSV-2+, HSV-1+17 (44)18 (42)
    HSV-2+, HSV-118 (46)23 (53)
    HSV-2, HSV-1+2 (5)2 (5)
    HSV-2, HSV-11 (3)0 (0)
    HSV-2 unknown, HSV-1+1 (3)0 (0)
Baseline HSV lesion(s)
    Median total lesion size in mm225.016.00.118‡
    Median no. of lesions (range)1 (1-4)1 (1-2)0.260‡
Log10 HSV copies
    Median (range)0 (0-14)5 (0-13)
    Mean (SD)4.5 (5.07)5.1 (5.09)
  • a The overall P value is given. *, Analysis of variance model with a term for treatment; †, two-sided Fisher exact test (race was grouped as white versus nonwhite); ‡, Wilcoxon rank sum.